-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A previous study reported a 35-gene expression classifier that identified four clear cell renal cell carcinoma groups (CCRCC1-CCRCC4) with distinct tumor microenvironments and predicted the response of metastatic clear cell renal cell carcinoma to sunitinib.
This study aimed to evaluate the efficacy and tolerability of nivolumab, nivolumab-ipilimumab, and VEGFR tyrosine kinase inhibitors (VEGFR-TKIs) in patients with different tumor molecular profiles
This study aimed to evaluate the efficacy and tolerability of nivolumab, nivolumab-ipilimumab, and VEGFR tyrosine kinase inhibitors (VEGFR-TKIs) in patients with different tumor molecular profiles
This is a multicenter, open-label, non-comparative, randomized, phase 2 trial recruiting patients 18 years of age and older with ECOG performance status 0-2 with previously untreated metastatic clear cell renal cell carcinoma
Between June 28, 2017, and July 18, 2019, a total of 303 patients were screened, of whom 202 were randomly assigned to each treatment group: 61 in the nivolumab group, nivolumab-ipilimumab 101 in the anti group and 40 in the VEGFR-TKI group
In the CCRCC1 group, 12 of 42 patients (29%) in the nivolumab group achieved an objective response and 16 of 41 patients (39%) in the nivolumab-ipilimumab group achieved an objective response (odds ratio [OR] 0.
The most common treatment-related grade 3-4 adverse events were hepatic failure and lipase elevation (3%) in the nivolumab group and lipase elevation and lipase elevation in the nivolumab-ipilimumab group Dysfunction (6%), and hypertension (15%) was most common in the VEGFR-TKI group
Original source:
Original source:Yann-Alexandre Vano, et al.
Yann-Alexandre Vano, et al.
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
The Lancet Oncology.
April 04, 2022.
https://doi.
org/10.
1016/S1470-2045(22)00128-0
Leave a comment here
